Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

G2G Bio partners with Boehringer Ingelheim to develop long-lasting injectable drug G2G Bio collaborates with Boehringer Ingelheim to innovate in injectable drug development ...

Boehringer Ingelheim ... weeks of treatment. "The initiation of this new trial marks an important study as it may provide us with further insight into treating patients with type 2 diabetes ...

Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, producers, and ...

Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue.1,2,3,4SPEVIGO's ...

BURLINGTON, ON, Feb. 5, 2025 /CNW/ - Boehringer Ingelheim Canada announces that intravenous and subcutaneous supplies of SPEVIGO ® (spesolimab injection/spesolimab for injection) are now available in ...

The global veterinary eye care market size is estimated to grow by USD 1.05 billion from 2024-2028, according to Technavio.

The Lipodystrophy market growth is driven by factors like increase in the prevalence of Lipodystrophy, investments in research and development, entry of emerging therapies during the study period 2020 ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks Consensus Estimate of $5.03 per share. Earnings rose 114% year over year.

Boehringer Ingelheim ... who received stable antipsychotic treatment. 2-6 The CONNEX clinical program enrolled 1,840 patients in 41 countries. 4-6 Boehringer Ingelheim decided to discontinue ...